BCTX
BriaCell·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 3
Ample Liquidity
Significant Net Income Decline
EPS Beats Expectation
Price Hits New Low
Price Hits 52-week Low
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BCTX
Briacell Therapeutics Corp.
A clinical-stage biotechnology company that specializing in targeted immunotherapies for cancer
Suite 300 - 235 15th Street, West Vancouver, BC V7T 2X1
--
BriaCell Therapeutics Corp. was founded in British Columbia on July 26, 2006. The company is a clinical-stage biotechnology company that is developing new immunotherapies to transform cancer treatment. Immunotherapies are at the forefront of the fight against cancer because they use the body's own immune system to identify and destroy cancer cells. The company is currently advancing a pivotal Phase 1 Phase 3 study of its Bria-IMT targeted immunotherapy in combination with immune checkpoint inhibitors for advanced metastatic breast cancer.
Company Financials
EPS
BCTX has released its 2025 Q3 earnings. EPS was reported at -1.64, versus the expected 0, missing expectations. The chart below visualizes how BCTX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
